China SXT Pharmaceuticals, Inc. Announces Share Consolidation

Core Viewpoint - China SXT Pharmaceutics, Inc. will implement a share consolidation at a ratio of 1-for-8 effective February 25, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2]. Company Actions - The Board of Directors approved the share consolidation to regain compliance with Nasdaq's minimum bid price requirement, which necessitates a closing bid price of$1.00 or more for at least ten consecutive trading days by April 1, 2025 [2]. - Following the share consolidation, every eight shares will be consolidated into one ordinary share, with no fractional shares issued; any fractional shares will be rounded up to one ordinary share [3]. Shareholder Impact - Shareholders holding shares through banks, brokers, or other nominees will have their shares automatically adjusted to reflect the consolidation [4]. - Beneficial holders are advised to contact their bank, broker, or nominee for further information regarding the share consolidation [4]. Company Overview - China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company established in 2005, focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces [5].